ASH develops and publishes evidence-based clinical practice guidelines to help practicing hematologists and other clinicians improve the quality of patient care. ASH’s guideline development is overseen by the ASH Guideline Oversight Subcommittee, which reports to the ASH Committee on Quality. This subcommittee selects guideline topics, vets and appoints individuals to serve on guideline panels, and determines policies and procedures for guideline development.
Browse the existing guidelines below, and learn about guidelines currently in development, including those open for public comment. ASH also endorses other clinical guidelines of relevance to practicing hematologists.
A collaboration with the McMaster University GRADE Centre, 10 guidelines on the prevention, diagnosis, and treatment of venous thromboembolism.
ASH is collaborating with ISTH, NHF, WFH, and the University of Kansas Medical Center to develop two guidelines on the diagnosis and management of von Willebrand disease.
Five new guidelines, currently in development, on the management of acute and chronic complications of sickle cell disease.
This ASH-ASCO guideline features the latest research and guidelines about the use of epoetin for the treatment of cancer-related anemia.
An update to the 2011 ASH clinical practice guidelines on immune thrombocytopenia (ITP). This guideline will address management of ITP in adult and pediatric patients.
Published in partnership with the College of American Pathologists, this guideline addresses the initial work-up of acute leukemia.
A new guideline collaboration with the American Society for Clinical Pathology and the College of American Pathologists on laboratory workup of lymphoma.
Clinical practice guidelines addressing treatment of acute myeloid leukemia in older adults.
Venous Thromboembolism (VTE)
Learn more about the VTE guidelines.back to top
Von Willebrand Disease (VWD)
Guidelines on the Diagnosis and Management of VWD
The American Society of Hematology (ASH), in collaboration with the International Society on Thrombosis and Haemostasis (ISTH), National Hemophilia Foundation (NHF), and World Federation of Hemophilia (WFH), is developing clinical practice guidelines on the diagnosis and management of VWD. Publication of the guidelines is anticipated in 2020.
VWD is a rare disease, but it is one of the most common bleeding disorders in the United States, affecting up to 1 percent of the general population. According to a 2015 report by the NHF, there is variation in clinical practice in both the diagnosis and management of the disease.back to top
Sickle Cell Disease (SCD)
ASH is developing new clinical practice guidelines on the management of acute and chronic complications of sickle cell disease (SCD). Topics to be addressed include pain, cerebrovascular disease, cardiopulmonary and kidney disease, stem cell transplantation, and transfusion support.
Publication of the five guidelines is anticipated in 2019.back to top
Epoetin and Darbepoetin
"ASH-American Society of Clinical Oncology (ASCO) 2010 clinical practice guideline update on the use of epoetin and darbepoetin"
Published in Blood on November 18, 2010, this guideline features the latest research and evidence-based clinical guidelines about the use of epoetin for the treatment of cancer-related anemia.back to top
Clinical Practice Guideline on the Evaluation and Management of ITP
Published in Blood on April 21, 2011, this guideline is an evidence-based analysis of the diagnosis and management of idiopathic thrombocytopenia developed by a panel of specialists sponsored by ASH.
In 2015, ASH convened an expert panel to revise the 2011 guidelines. Systematic evidence review and methodological support for these guidelines is provided by the University of Oklahoma Health Sciences Center. Publication of the revised guidelines is expected in 2019.back to top
Initial Workup of Acute Leukemia
"Initial Diagnostic Work-up of Acute Leukemia: Guideline From the College of American Pathologists and the American Society of Hematology"
On February 22, 2017, the College of American Pathologists (CAP) and the American Society of Hematology (ASH) published an evidence-based guideline that addresses the initial work-up of acute leukemia. The guideline was published in an early online edition of the Archives of Pathology and Laboratory Medicine.
The guideline defines the recommended clinical information and laboratory testing needed for proper diagnosis, with the goal of optimal prognosis of pediatric and adult patients with acute myeloid leukemia (AML), acute lymphocytic leukemia (ALL), and mixed-phenotype acute leukemia (MPAL).
ASH and CAP have provided a mini-review that explains the impetus for the guideline and outlines the
The guideline recommendations are also available as a printed pocket
guide and in the ASH Pocket Guides app (available on iOS and Android).back to top
Laboratory Workup of Lymphoma
The American Society for Clinical Pathology (ASCP), the College of American Pathologists (CAP), and the American Society of Hematology (ASH) are collaborating to develop a practice guideline on the laboratory workup of patients with suspected lymphoma.
An expert panel formed in 2017 includes both hematopathologists and clinical hematologists representing the three collaborating organizations. The guideline will address laboratory ordering and communications, specimen handling, and diagnostic and prognostic testing including molecular testing.back to top
Acute Myeloid Leukemia
ASH is developing new clinical practice guidelines on the management of acute myeloid leukemia (AML) in older adults. The systematic evidence review and methodological support for these guidelines is being provided by McMaster University. AML affects 61,000 new patients each year. Most of these patients are adults, and the average age of patients in 67 years old.
Publication of the guidelines is expected in 2020.
back to top